Here we discuss the molecular mechanisms leading to the development of hepatocellular carcinoma focusing on the latest developments in liver magnetic resonance imaging, CTC, and radiomic technology and their potential to improve diagnosis, staging, and therapy
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Personalized care in oncology is expected to significantly improve morbidity and mortality, facilitated by our increasing understanding of the molecular mechanisms driving tumors and the ability to target those drivers.
📊
Key Findings & Data:Radiomics, the use of imaging technology to extrapolate molecular tumor data, and the detection of circulating tumor cells (CTCs) are two new technologies that could be incorporated into the clinical setting with relative ease.
💡
Conclusion & Impact:Here we discuss the molecular mechanisms leading to the development of hepatocellular carcinoma focusing on the latest developments in liver magnetic resonance imaging, CTC, and radiomic technology and their potential to improve diagnosis, staging, and therapy
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Personalized care in oncology is expected to significantly improve morbidity and mortality, facilitated by our increasing understanding of the molecular mechanisms driving tumors and the ability to target those drivers. Hepatocellular carcinoma has a very high mortality to incidence ratio despite localized disease being curable, emphasizing the importance of early diagnosis. Radiomics, the use of imaging technology to extrapolate molecular tumor data, and the detection of circulating tumor cells (CTCs) are two new technologies that could be incorporated into the clinical setting with relative ease. Here we discuss the molecular mechanisms leading to the development of hepatocellular carcinoma focusing on the latest developments in liver magnetic resonance imaging, CTC, and radiomic technology and their potential to improve diagnosis, staging, and therapy
🔖
Cite This Article
HESKETH, R. L., ZHU, A. X., OKLU, R. (2015). Radiomics and circulating tumor cells: personalized care in hepatocellular carcinoma?. Diagnostic and Interventional Radiology, Cilt: 21 - Sayı: 1, 78–84. https://ajindex.com/articles/214144
Goldzieher M, Bokay Z. Der primare Leb- er Krebs. Virchows Arch (A) 1911:75-131. [CrossRef] Cancer Incidence and Mortality World- wide. Available at: http://www.wcrf.org/ cancer_statistics/world_cancer_statistics. php. Accessed May 25, 2014.
Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treat- ment of hepatocellular carcinoma. Liver Transpl 2004; 10:S115-120. [CrossRef] Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepa- tocellular carcinoma: Chemoemboliza- tion improves survival. Hepatology 2003; 37:429-442. [CrossRef] Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB. Use of surveillance for hepatocellular carcino- ma among patients with cirrhosis in the United States. Hepatology 2010; 52:132- 141. [CrossRef] Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epide- miology of hepatocellular carcinoma: a global and regional perspective. Oncolo- gist 2010; 4:5-13. [CrossRef] Morgan TR, Mandayam S, Jamal MM. Alco- hol and hepatocellular carcinoma. Gastro- enterology 2004; 127:87-96. [CrossRef] Ni YH, Chen DS. Hepatitis B vaccina- tion in children: the Taiwan experience. Pathol Biol 2010; 58:296-300. [CrossRef] Herath NI, Leggett BA, MacDonald GA. Re- view of genetic and epigenetic alterations in hepatocarcinogenesis. J Gastroenterol Hepatol 2006; 21:15-21. [CrossRef] Aguilar F, Hussain SP, Cerutti P. Aflatoxin B1 induces the transversion of G-->T in co- don 249 of the p53 tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci USA 1993; 90:8586-8590. [CrossRef] Neuveut C, Wei Y, Buendia MA. Mecha- nisms of HBV-related hepatocarcinogene- sis. J Hepatol 2010; 52:594-604. [CrossRef] Moinzadeh P, Breuhahn K, Stutzer H, Schir- macher P. Chromosome alterations in hu- man hepatocellular carcinomas correlate with aetiology and histological grade--re- sults of an explorative CGH meta-analysis. Br J Cancer 2005; 92:935-941.
Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer 2013; 13:123-135. [CrossRef] Higgs MR, Lerat H, Pawlotsky JM. Hep- atitis C virus-induced activation of [beta]-catenin promotes c-Myc expres- sion and a cascade of pro-carcinogenetic events. Oncogene 2013; 32:4683-4693. [CrossRef] Bamford S, Dawson E, Forbes S, et al. The COSMIC (Catalogue of Somatic Muta- tions in Cancer) database and website. Br J Cancer 2004; 91:355-358.